Globus Medical Reports Record Q4 2025 Earnings and Growth Momentum
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 hour ago
0mins
Should l Buy GMED?
Source: seekingalpha
- Significant Revenue Growth: Globus Medical reported Q4 2025 revenue of $826.4 million, a 25.7% increase year-over-year, with non-GAAP EPS reaching $1.28, reflecting a 52.1% rise over Q4 2024, showcasing strong market performance and enhanced profitability.
- Sustained Spine Business Growth: The U.S. spine business grew by 10% in Q4, marking 48 consecutive weeks of growth, indicating robust development in core business areas and expected further market share gains.
- Product Innovation Launches: Six new spine products were launched in 2025, with four introduced in Q4, particularly the DuraPro power tools receiving positive feedback from surgeons, enhancing the company's competitive edge in the surgical equipment market.
- Optimistic 2026 Outlook: The company reaffirmed its 2026 revenue guidance of $3.18 billion to $3.22 billion and raised non-GAAP EPS expectations to $4.40 to $4.50, reflecting management's confidence in sustained profitability and market growth.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy GMED?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on GMED
Wall Street analysts forecast GMED stock price to rise
13 Analyst Rating
9 Buy
4 Hold
0 Sell
Moderate Buy
Current: 93.400
Low
87.00
Averages
101.00
High
114.00
Current: 93.400
Low
87.00
Averages
101.00
High
114.00
About GMED
Globus Medical, Inc. is a medical device company that develops and commercializes healthcare solutions with a focus on improving the quality of life of patients with musculoskeletal disorders. The Company offers a portfolio of differentiated technologies that are used to treat a variety of musculoskeletal conditions. Musculoskeletal Solutions consist primarily of implantable devices, biologics, accessories, and surgical instruments used in a range of spinal, orthopedic and neurosurgical procedures. Its spine products address the conditions affecting the spine, including degenerative conditions, deformities, tumors, and trauma. It provides solutions that facilitate both open and minimally invasive surgery techniques. It includes traditional fusion implants, such as pedicle screws and rod systems, and others. Its orthopedic trauma solutions are designed to treat a variety of orthopedic fracture patterns and patient anatomies in the upper and lower extremities, as well as the hip.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Globus Medical Reports Record Q4 2025 Earnings and Growth Momentum
- Significant Revenue Growth: Globus Medical reported Q4 2025 revenue of $826.4 million, a 25.7% increase year-over-year, with non-GAAP EPS reaching $1.28, reflecting a 52.1% rise over Q4 2024, showcasing strong market performance and enhanced profitability.
- Sustained Spine Business Growth: The U.S. spine business grew by 10% in Q4, marking 48 consecutive weeks of growth, indicating robust development in core business areas and expected further market share gains.
- Product Innovation Launches: Six new spine products were launched in 2025, with four introduced in Q4, particularly the DuraPro power tools receiving positive feedback from surgeons, enhancing the company's competitive edge in the surgical equipment market.
- Optimistic 2026 Outlook: The company reaffirmed its 2026 revenue guidance of $3.18 billion to $3.22 billion and raised non-GAAP EPS expectations to $4.40 to $4.50, reflecting management's confidence in sustained profitability and market growth.
See More
Globus Medical Reports Significant Q4 Earnings Growth
- Significant Earnings Increase: Globus Medical's Q4 net income reached $140.59 million, translating to $1.03 per share, a substantial rise from last year's $26.50 million and $0.19 per share, indicating robust profitability and market demand.
- Adjusted Earnings Growth: Excluding special items, adjusted earnings stood at $174.59 million, or $1.28 per share, reflecting the company's success in cost control and operational efficiency, which further bolsters investor confidence.
- Revenue Surge: The company's Q4 revenue grew by 25.7% to $826.42 million, up from $657.29 million last year, demonstrating strong performance in the medical device market and an expansion of market share.
- Optimistic Market Outlook: With the ongoing demand for medical devices, Globus Medical's performance not only enhances its competitive position but also provides a solid financial foundation for future expansion and investment.
See More
Datadog Shares Drop 11% Amid AI Tool Concerns
- Datadog Stock Decline: Datadog (DDOG) shares fell 11% yesterday due to concerns over Anthropic's new feature, Claude Code Security, which raised fears of further disruption in cybersecurity stocks, reflecting market anxiety about AI's impact.
- AI Tool Impact Analysis: Anthropic described its tool as capable of scanning codebases for security vulnerabilities and suggesting targeted software patches, arriving at a pivotal moment for cybersecurity; however, analysts believe the market's reaction may be overblown given Datadog's strong fundamentals.
- Robust Revenue Growth: Despite market fears, Datadog reported a 25% year-over-year revenue growth and a net retention rate exceeding 110%, indicating a sticky customer base and resilience in its business model, suggesting the company remains competitive.
- Market Reaction and Investment Strategy: Analyst Sanmeet Deo emphasized that while market sentiment is low, investors should remain patient and avoid making hasty decisions based on short-term fluctuations, as history shows that long-term holding often proves to be the wisest strategy.
See More
Globus Medical Set to Announce Q4 Earnings with Strong Estimates
- Earnings Announcement Date: Globus Medical is set to release its Q4 earnings on February 24 after market close, with a consensus EPS estimate of $1.15, reflecting a 36.9% year-over-year increase, which could further solidify its growth momentum in the medical device sector.
- Strong Revenue Expectations: The anticipated revenue for Q4 is $803.29 million, representing a 22.2% year-over-year growth, indicating the company's sustained strong performance in market demand and product sales, potentially driving stock price appreciation.
- Historical Performance Review: Over the past two years, Globus Medical has beaten EPS estimates 75% of the time and revenue estimates 88% of the time, enhancing investor confidence and potentially attracting more institutional investors due to its consistent performance.
- Expectation Revisions: In the last three months, EPS estimates have seen six upward revisions and no downward adjustments, while revenue estimates experienced five upward revisions and one downward, reflecting analysts' optimistic outlook on the company's future performance, which may further boost stock prices.
See More
Globus Medical Upgraded to Buy by Needham with $112 Target
- Rating Upgrade: Needham upgraded Globus Medical Inc. (NYSE:GMED) from Hold to Buy with a price target of $112, reflecting positive expectations for the company's financial performance following its preliminary fourth-quarter revenue announcement.
- Improved Earnings Outlook: Analysts at Needham highlighted expanding EBITDA margins, particularly an estimated 20% EBITDA margin for Nevro, which is expected to drive earnings expectations for fiscal 2026, potentially lifting earnings per share guidance by a high-single to low-double digit percentage.
- Organic Growth Potential: The analysts believe that improving organic revenue growth could lead to upside relative to Globus's existing revenue guidance, further enhancing investor confidence in the company's prospects.
- International Market Expansion: On January 26, TD Cowen initiated coverage on Globus with a Buy rating and a $110 price target, noting growth opportunities in its Nevro segment, international market expansion, and enabling technologies, despite facing significant negative sentiment, the long-term earnings outlook remains favorable.
See More
Geneva Capital Sells Shares of Ollie's Bargain Outlet
- Share Sale Details: Geneva Capital Management sold 95,151 shares of Ollie's Bargain Outlet in Q4 2026, with an estimated transaction value of $11.47 million, demonstrating the firm's adaptability amid market fluctuations.
- Ownership Percentage Change: Following the sale, Geneva's stake in Ollie's decreased from 2.34% to 2.13%, indicating a cautious approach towards the stock while still retaining a degree of investment confidence.
- Market Performance Analysis: As of February 11, 2026, Ollie's shares were priced at $113.75, reflecting a 10% increase over the year, yet underperforming the S&P 500 by 4.39 percentage points, suggesting mixed market expectations for future growth.
- Expansion Plans: Ollie's opened 86 new stores and acquired Big Lots in fiscal 2025, showcasing its commitment to expansion in an uncertain economic environment, potentially laying the groundwork for future revenue growth.
See More
Globus Medical Reports Record Q4 2025 Earnings and Growth Momentum
- Significant Revenue Growth: Globus Medical reported Q4 2025 revenue of $826.4 million, a 25.7% increase year-over-year, with non-GAAP EPS reaching $1.28, reflecting a 52.1% rise over Q4 2024, showcasing strong market performance and enhanced profitability.
- Sustained Spine Business Growth: The U.S. spine business grew by 10% in Q4, marking 48 consecutive weeks of growth, indicating robust development in core business areas and expected further market share gains.
- Product Innovation Launches: Six new spine products were launched in 2025, with four introduced in Q4, particularly the DuraPro power tools receiving positive feedback from surgeons, enhancing the company's competitive edge in the surgical equipment market.
- Optimistic 2026 Outlook: The company reaffirmed its 2026 revenue guidance of $3.18 billion to $3.22 billion and raised non-GAAP EPS expectations to $4.40 to $4.50, reflecting management's confidence in sustained profitability and market growth.
See More
Globus Medical Reports Significant Q4 Earnings Growth
- Significant Earnings Increase: Globus Medical's Q4 net income reached $140.59 million, translating to $1.03 per share, a substantial rise from last year's $26.50 million and $0.19 per share, indicating robust profitability and market demand.
- Adjusted Earnings Growth: Excluding special items, adjusted earnings stood at $174.59 million, or $1.28 per share, reflecting the company's success in cost control and operational efficiency, which further bolsters investor confidence.
- Revenue Surge: The company's Q4 revenue grew by 25.7% to $826.42 million, up from $657.29 million last year, demonstrating strong performance in the medical device market and an expansion of market share.
- Optimistic Market Outlook: With the ongoing demand for medical devices, Globus Medical's performance not only enhances its competitive position but also provides a solid financial foundation for future expansion and investment.
See More
Datadog Shares Drop 11% Amid AI Tool Concerns
- Datadog Stock Decline: Datadog (DDOG) shares fell 11% yesterday due to concerns over Anthropic's new feature, Claude Code Security, which raised fears of further disruption in cybersecurity stocks, reflecting market anxiety about AI's impact.
- AI Tool Impact Analysis: Anthropic described its tool as capable of scanning codebases for security vulnerabilities and suggesting targeted software patches, arriving at a pivotal moment for cybersecurity; however, analysts believe the market's reaction may be overblown given Datadog's strong fundamentals.
- Robust Revenue Growth: Despite market fears, Datadog reported a 25% year-over-year revenue growth and a net retention rate exceeding 110%, indicating a sticky customer base and resilience in its business model, suggesting the company remains competitive.
- Market Reaction and Investment Strategy: Analyst Sanmeet Deo emphasized that while market sentiment is low, investors should remain patient and avoid making hasty decisions based on short-term fluctuations, as history shows that long-term holding often proves to be the wisest strategy.
See More
Globus Medical Set to Announce Q4 Earnings with Strong Estimates
- Earnings Announcement Date: Globus Medical is set to release its Q4 earnings on February 24 after market close, with a consensus EPS estimate of $1.15, reflecting a 36.9% year-over-year increase, which could further solidify its growth momentum in the medical device sector.
- Strong Revenue Expectations: The anticipated revenue for Q4 is $803.29 million, representing a 22.2% year-over-year growth, indicating the company's sustained strong performance in market demand and product sales, potentially driving stock price appreciation.
- Historical Performance Review: Over the past two years, Globus Medical has beaten EPS estimates 75% of the time and revenue estimates 88% of the time, enhancing investor confidence and potentially attracting more institutional investors due to its consistent performance.
- Expectation Revisions: In the last three months, EPS estimates have seen six upward revisions and no downward adjustments, while revenue estimates experienced five upward revisions and one downward, reflecting analysts' optimistic outlook on the company's future performance, which may further boost stock prices.
See More
Globus Medical Upgraded to Buy by Needham with $112 Target
- Rating Upgrade: Needham upgraded Globus Medical Inc. (NYSE:GMED) from Hold to Buy with a price target of $112, reflecting positive expectations for the company's financial performance following its preliminary fourth-quarter revenue announcement.
- Improved Earnings Outlook: Analysts at Needham highlighted expanding EBITDA margins, particularly an estimated 20% EBITDA margin for Nevro, which is expected to drive earnings expectations for fiscal 2026, potentially lifting earnings per share guidance by a high-single to low-double digit percentage.
- Organic Growth Potential: The analysts believe that improving organic revenue growth could lead to upside relative to Globus's existing revenue guidance, further enhancing investor confidence in the company's prospects.
- International Market Expansion: On January 26, TD Cowen initiated coverage on Globus with a Buy rating and a $110 price target, noting growth opportunities in its Nevro segment, international market expansion, and enabling technologies, despite facing significant negative sentiment, the long-term earnings outlook remains favorable.
See More
Geneva Capital Sells Shares of Ollie's Bargain Outlet
- Share Sale Details: Geneva Capital Management sold 95,151 shares of Ollie's Bargain Outlet in Q4 2026, with an estimated transaction value of $11.47 million, demonstrating the firm's adaptability amid market fluctuations.
- Ownership Percentage Change: Following the sale, Geneva's stake in Ollie's decreased from 2.34% to 2.13%, indicating a cautious approach towards the stock while still retaining a degree of investment confidence.
- Market Performance Analysis: As of February 11, 2026, Ollie's shares were priced at $113.75, reflecting a 10% increase over the year, yet underperforming the S&P 500 by 4.39 percentage points, suggesting mixed market expectations for future growth.
- Expansion Plans: Ollie's opened 86 new stores and acquired Big Lots in fiscal 2025, showcasing its commitment to expansion in an uncertain economic environment, potentially laying the groundwork for future revenue growth.
See More
